All Stories

  1. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations

    Article • BMC Medical Genetics, April 2015, Springer Science + Business Media

    Dr Tomasz A Stoklosa

  2. Correction to Bright, Color-Tunable Fluorescent Dyes Based on π-Expanded Diketopyrrolopyrroles

    Article • Organic Letters, January 2015, American Chemical Society (ACS)

    Dr Tomasz A Stoklosa

  3. BRAF — A new player in hematological neoplasms

    Article • Blood Cells Molecules and Diseases, June 2014, Elsevier

    Dr Tomasz A Stoklosa

  4. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib

    Article • Experimental Hematology, June 2014, Elsevier

    Dr Tomasz A Stoklosa

  5. Differential expression ofBIRCfamily genes in chronic myeloid leukaemia -BIRC3andBIRC8as potential new candidates to identify disease progression

    Article • British Journal of Haematology, November 2013, Wiley

    Dr Tomasz A Stoklosa

  6. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia

    Article • Experimental Hematology, May 2013, Elsevier

    Dr Tomasz A Stoklosa

  7. Cover Picture: Synthesis and Optical Properties of Tetraaryl-1,4-dihydropyrrolo[3,2-b]pyrroles (Asian J. Org. Chem. 5/2013)

    Article • Asian Journal of Organic Chemistry, May 2013, Wiley

    Dr Tomasz A Stoklosa

  8. Synthesis and Optical Properties of Tetraaryl-1,4-dihydropyrrolo[3,2-b]pyrroles

    Article • Asian Journal of Organic Chemistry, February 2013, Wiley

    Dr Tomasz A Stoklosa

  9. The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells

    Article • Cell Cycle, November 2012, Taylor & Francis

    Dr Tomasz A Stoklosa

  10. Bright, Color-Tunable Fluorescent Dyes Based on π-Expanded Diketopyrrolopyrroles

    Article • Organic Letters, June 2012, American Chemical Society (ACS)

    Dr Tomasz A Stoklosa

  11. Terapia przewlekłej białaczki szpikowej – teraźniejszość i wyzwania na przyszłość

    Article • Acta Haematologica Polonica, January 2012, Elsevier

    Dr Tomasz A Stoklosa

  12. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice

    Article • BMC Cancer, July 2008, Springer Science + Business Media

    Dr Tomasz A Stoklosa, Dr Jacek Bil

  13. Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

    Article • PLoS Medicine, March 2008, PLOS

    Dr Tomasz A Stoklosa, Dr Jacek Bil

  14. Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin

    Article • International Journal of Oncology, January 2008, Spandidos Publications

    Dr Tomasz A Stoklosa

  15. Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

    Article • International Journal of Oncology, December 2007, Spandidos Publications

    Dr Tomasz A Stoklosa

  16. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo

    Article • International Journal of Oncology, June 2007, Spandidos Publications

    Dr Tomasz A Stoklosa

  17. ATR-Chk1 Axis Protects BCR/ABL Leukemia Cells from the Lethal Effect of DNA Double-Strand Breaks

    Article • Cell Cycle, April 2006, Taylor & Francis

    Dr Tomasz A Stoklosa

  18. The influence of photodynamic therapy on the immune response

    Article • Photodiagnosis and Photodynamic Therapy, December 2005, Elsevier

    Dr Tomasz A Stoklosa

  19. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence

    Article • Oncogene, March 2005, Springer Science + Business Media

    Dr Tomasz A Stoklosa

  20. BCR/ABL Recruits p53 Tumor Suppressor Protein to Induce Drug Resistance

    Article • Cell Cycle, November 2004, Taylor & Francis

    Dr Tomasz A Stoklosa

  21. A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index

    Article • Oncology Reports, September 2002, Spandidos Publications

    Dr Tomasz A Stoklosa

  22. Lovastatin and simvastatin are modulators of the proteasome

    Article • The International Journal of Biochemistry & Cell Biology, September 2000, Elsevier

    Dr Tomasz A Stoklosa

  23. Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/β-lactone is not a specific inhibitor of the proteasome

    Article • The International Journal of Biochemistry & Cell Biology, July 2000, Elsevier

    Dr Tomasz A Stoklosa

  24. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice

    Article • Life Sciences, February 2000, Elsevier

    Dr Tomasz A Stoklosa

  25. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production

    Article • Cancer Letters, December 1999, Elsevier

    Dr Tomasz A Stoklosa

  26. Effective chemo-immunotherapy of L1210 leukemiain vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin

    Article • International Journal of Cancer, August 1998, Wiley

    Dr Tomasz A Stoklosa

  27. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation betweenin vitro andin vivo results

    Article • International Journal of Cancer, May 1996, Wiley

    Dr Tomasz A Stoklosa

  28. Potentiation of the anti‐tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results

    Article • International Journal of Cancer, May 1996, Wiley

    Dr Tomasz A Stoklosa